Xinlitan (allisartan) / Allist - LARVOL DELTA

Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patients. (PubMed, J Geriatr Cardiol) - "In elderly patients with hypertension, sacubitril/allisartan provided dose-dependent greater blood pressure reductions compared with olmesartan."

Clinical • Journal • Cardiovascular • Hypertension

IPAD: Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=11414 | Recruiting | Sponsor: XueQing Yu | Trial completion date: Sep 2025 ➔ Sep 2029 | Trial primary completion date: Sep 2025 ➔ Sep 2028

Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Monotherapy • Cardiovascular • Hypertension

Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. (PubMed, Am J Cardiovasc Drugs) - "This study supports that ARBs with inverse agonism, especially AZL-M, have a better BP-lowering efficacy compared with ARBs without inverse agonism and ARNIs, while maintaining favorable safety profiles. Future research is encouraged to explore the effects on long-term outcomes, combination therapies, and safety in diverse populations."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan (clinicaltrials.gov) - P3 | N=346 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P3 trial • Cardiovascular • Hypertension

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine (clinicaltrials.gov) - P3 | N=376 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P3 trial • Cardiovascular • Hypertension

Effects of Sacubitril/Allisartan versus Olmesartan on serum uric acid in Chinese patients with hypertension and hyperuricaemia. (PubMed, Hypertens Res) - "Several angiotensin receptor blockers, such as losartan, can decrease serum uric acid level, but the effect on serum uric acid of angiotensin receptor neprilysin inhibitor remains unclear. Least square mean changes in serum uric acid reductions were greater with Sacubitril/Allisartan versus Olmesartan, with a difference of -30.0 μmol/L (P = 0.01) for Sacubitril/Allisartan 240 mg and -35.6 μmol/L (P = 0.002) for Sacubitril/Allisartan 480 mg. Treatment with Sacubitril/Allisartan decreased serum uric acid levels significantly more than Olmesartan in Chinese patients with both hypertension and hyperuricaemia, demonstrating a unique uricosuric effect of Sacubitril/Allisartan."

Journal • Cardiovascular • Hypertension

Sacubitril/Allisartan Versus Amlodipine for Hypertensive Patients With Overweight or Obesity: A Multicenter, Open-Label, Randomized Controlled Trial (ChiCTR) - P=N/A | N=104 | Not yet recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New trial • Cardiovascular • Genetic Disorders • Hypertension • Obesity

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. (PubMed, BMC Cardiovasc Disord) - "Based on the only available eligible evidence, the combination of losartan and amlodipine was the optimal dual therapy for Chinese patients with hypertension and hyperuricemia, while allisartan and losartan were the most effective monotherapies for lowering serum uric acid. These findings are not generalizable to non-Chinese populations, reflecting a gap in global evidence rather than intentional study scope restriction."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

SHOT: Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity (clinicaltrials.gov) - P4 | N=104 | Not yet recruiting | Sponsor: Jing Liu

New P4 trial • Cardiovascular • Genetic Disorders • Hypertension • Obesity

Promising efficacy of alisartan isoproxil combined with probiotics in elderly hypertensive patients and analysis of cardiovascular prognostic factors. (PubMed, Am J Transl Res) - "Alisartan isoproxil combined with probiotics effectively improves blood pressure, inflammatory markers, blood lipids, and vascular endothelial function in elderly hypertensive patients. Age, BMI, SBP, and DBP are identified as risk factors for MACE and should be addressed early with preventive interventions."

Biomarker • Journal • Cardiovascular • Hypertension • EDN1

Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - "This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP."

Clinical • Journal • Cardiovascular • Hypertension

Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants (clinicaltrials.gov) - P4 | N=54 | Recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P4 trial

Sacubitril/Allisartan in hyperuricemia (ESC-WCC 2025) - No abstract available

Late-breaking abstract • Cardiovascular • Hypertension

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Dec 2026 ➔ Sep 2026

Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

Antihypertensive potential of diosgenin: A comparative pharmacoinformatics study. (PubMed, Comput Biol Med) - "This study explores the antihypertensive potential of thirty-six natural terpenoids targeting the AT1R, with Allisartan isoproxil (active form, LCA) used as a positive control...Additionally, PPI network and hub genes analysis identified potential molecular targets for Diosgenin, including SRC, ABL1, IGF1R, and JAK2, suggesting possible mechanistic role. Diosgenin is a promising natural therapeutic candidate for hypertension treatment, which could regulate vascular function, smooth muscle cell activity, and endothelial function via various mechanisms by influencing IGF1R, JAK2, KIT, MDM2, MET, and IL2 demonstrated through KEGG pathway analysis."

Journal • Cardiovascular • Hypertension • ABL1 • IL2 • JAK2

A correlative study of the effect of allisartan isoproxil on sexual function and nocturnal blood pressure in male patients with mild to moderate hypertension (ChiCTR) - P4 | N=111 | Completed | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New P4 trial • Cardiovascular • Hypertension

Effects of Allisartan on Uric Acid, Left Atrial, Left Ventricular, and Artery Stiffness in Mild-to-Moderate Essential Hypertension. (PubMed, J Clin Hypertens (Greenwich)) - "In Conclusion, allisartan 240 mg and olmesartan 20 mg once daily achieve broadly similar reductions in blood pressure, improving left heart structure and function, mitigating arterial stiffness in individuals with mild-to-moderate essential hypertension. Compared to olmesartan, allisartan demonstrates significant reductions in serum UA."

Clinical • Journal • Cardiovascular • Hypertension

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study. (PubMed, J Hum Hypertens) - "AML/ALI combination was generally safe and well tolerated, with sustained efficacy up to 52 weeks. The study concluded that ALI/AML offers a convenient, single-pill option for effective BP reduction in hypertensive patients."

Journal • P3 data • Review • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

Blood pressure-lowering efficacy of Sacubitril/Allisartan versus Olmesartan in Chinese hypertensive patients with a nondipping blood pressure pattern. (PubMed, J Hypertens) - "Sacubitril/Allisartan is particularly effective in reducing nighttime blood pressure and in reversing the nondipping to dipping nighttime blood pressure pattern."

Clinical • Journal • Cardiovascular • Hypertension

Local structural dynamics and vibrational energy transfer in an angiotensin receptor-neprilysin inhibitor by ultrafast 2D IR spectroscopy. (PubMed, J Chem Phys) - "As a novel drug-drug cocrystal, sacubitril allisartan calcium (S086) has demonstrated significant efficacy in the treatment of hypertension and heart failure...Vibrational energy transfer between the bidentate and tridentate COO- groups in the α-crystal was found to be faster than that in the ξ-crystal, suggesting shorter intermolecular distances between EXP3174 and sacubitril in the former. These findings provide dynamical structural parameters that help to understand the stability and releasing mechanisms of the drug molecules."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Bioequivalence Study of Single Oral Dose of Allisartan Isoproxil and Amlodipine Besylate Tablets in Healthy Subjects under Fasting Conditions (ChiCTR) - P1 | N=50 | Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Second Affiliated Hospital of Guangzhou Medical University

New P1 trial • Cardiovascular • Hypertension

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - P3 | "This once-daily single-pill combination demonstrated promising efficacy and tolerability. Trial Registration: ClinicalTrials.gov identifier: NCT06465264."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

ANTI-MASK: Antihypertensive Treatment in Masked Hypertension (clinicaltrials.gov) - P4 | N=320 | Completed | Sponsor: Yan Li | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension